Histamine Analogue — Vestibular Pregnancy: There are no adequate data from use in pregnant women; animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity, embryonal/foetal development, parturition or postnatal development at clinically relevant therapeutic exposure. As a precautionary measure, it is preferable to AVOID the use of betahistine during pregnancy. Breast-feeding: it is not known whether betahistine is excreted in human milk (it is excreted in rat milk; post-partum effects in animal studies were limited to very high doses) — weigh the importance of the drug to the mother against the benefits of nursing and the potential risks to the child. Fertility: animal studies did not show effects on fertility in rats.

Betahistine

Brand names: Serc

Betahistine is an oral histamine analogue used to reduce the frequency and severity of vertigo, tinnitus and hearing loss associated with Meniere's disease; this page concerns its use in older patients.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Initial 8 to 16 mg three times daily; maintenance generally 24–48 mg daily

Route: Oral

Frequency: Three times daily initially; maintenance dose given in 2 or 3 divided doses throughout the day

Max: 48 mg daily

Ménière's disease / vestibular indication per the SPC. Take preferably with or after meals with a glass of water — betahistine may cause mild indigestion, and taking it with food may help relieve this. Dosage can be adjusted to suit individual patient needs. Sometimes improvement is observed only after a couple of weeks of treatment, and the best results are sometimes obtained after a few months; there are indications that treatment from the onset of the disease prevents progression and/or loss of hearing in later phases. Tablet-strength equivalents given in the SPC: 8 mg tablets — 1 to 2 tablets three times a day; 16 mg tablets — half to 1 tablet three times a day; 24 mg tablets — recommended starting dose is 24 mg, and if the maximum daily dose of 48 mg is indicated, one 24 mg tablet twice daily (morning and evening). ELDERLY (this page's focus): although there are limited data from clinical studies in this group, extensive post-marketing experience suggests that NO dose adjustment is necessary in the elderly. Paediatric: not recommended for use in children and adolescents below 18 years due to lack of data on safety and efficacy. Betahistine is not the appropriate treatment for benign paroxysmal vertigo or for dizziness related to central nervous system disease. Caution in peptic ulcer or a history of peptic ulceration, bronchial asthma, urticaria/rashes/allergic rhinitis, and severe hypotension. Source: eMC SPC for Betahistine 16 mg tablets (§4.2).

Dose adjustments

Renal

No specific clinical trials are available in patients with renal impairment, but according to post-marketing experience no dose adjustment appears to be necessary. Hepatic impairment: likewise, no dose adjustment appears to be necessary.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Hypersensitivity to the active substance or to any of the excipients
Phaeochromocytoma — as a synthetic analogue of histamine, betahistine may induce release of catecholamines from the tumour, resulting in severe hypertension

Side effects

Headache — common
Nausea and dyspepsia — common
Mild gastric complaints (e.g. vomiting, gastrointestinal pain, dry mouth, diarrhoea, abdominal distension and bloating) — frequency not known; can normally be managed by taking the dose during meals or lowering the dose
Hypersensitivity reactions, e.g. anaphylaxis — frequency not known
Cutaneous and subcutaneous hypersensitivity reactions, in particular angioneurotic oedema, urticaria, rash and pruritus — frequency not known
Thrombocytopenia — frequency not known

Interactions

Monoamine oxidase inhibitors, including MAO-B selective agents (e.g. selegiline) — in vitro data indicate inhibition of betahistine metabolism; caution is recommended with concomitant use
H1 antagonists (antihistamines) — concurrent administration may cause mutual attenuation of effect; antagonism is theoretically expected, although no such interactions have been reported
Ethanol — a case report of an interaction
A compound containing pyrimethamine with dapsone — a case report of an interaction
Salbutamol — a case report of potentiation of betahistine
No proven cases of hazardous interactions; no in-vivo interaction studies have been performed, and based on in-vitro data no in-vivo inhibition of cytochrome P450 enzymes is expected

Clinical monograph

How it works

It acts as a histamine H1 agonist and H3 antagonist, thought to improve microcirculation in the inner ear (stria vascularis) and modulate vestibular activity, reducing endolymphatic pressure.

Prescribing in practice

In older patients caution applies in active or past peptic ulcer disease and in asthma, as betahistine may aggravate these conditions.
It is best taken with food to reduce gastrointestinal upset.
Benefit on Meniere's symptoms is modest and variable, so review effectiveness and avoid attributing all balance problems in older people to a single cause.

Monitoring

Monitor clinically for change in vertigo frequency and severity and for gastrointestinal or respiratory adverse effects.

Counselling the patient

Take it with or after food.
Report worsening indigestion, stomach pain or wheeze.
Effects build over time and the medicine controls rather than cures symptoms.

Evidence & guidelines

Evidence for symptom benefit in Meniere's disease is limited and mixed, and use reflects the product SPC and specialist practice rather than a definitive landmark trial.

Reference: NICE Evidence Review (Betahistine for Meniere's); Cochrane Review (betahistine); BSA Meniere's guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways